Products
Pre-made Albiglutide benchmark antibody (Peptide Protein fusion , anti-GLP1R therapeutic antibody, Anti-GLP-1-R/GLP-1R Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-724
Pre-made Albiglutide benchmark antibody (Peptide Protein fusion , anti-GLP1R therapeutic antibody, Anti-GLP-1-R/GLP-1R Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes.
As of 217 it is unclear if it affects a person's risk of death.[1] GSK has announced that it intends to withdraw the drug from the worldwide market by July 218 for economic reasons.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-724-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-724-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-724-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-724-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Albiglutide Biosimilar, Peptide Protein Fusion targeting GLP1R: (Glp-1)2 Peptide-Albumin(Alb) Fusion Protein targetingGLP-1-R/GLP-1R |
| INN Name | Albiglutide |
| Target | GLP1R |
| Format | Peptide Protein fusion |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - (GCG (glucagon) 98-127 (glucagon-like peptide 1, GLP1) 7- 36)2 - ALB (albumin, human serum albumin, HSA) 25-609 |
| VD LC | Fusion - (GCG (glucagon) 98-127 (glucagon-like peptide 1, GLP1) 7- 36)2 - ALB (albumin, human serum albumin, HSA) 25-609 |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | GlaxoSmithKline (Brentford UK) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
